MedTrace Logo

Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score

NCT07093775 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2025-07-30

No results posted yet for this study

Summary

To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.

Conditions

Interventions

OTHER

Tumor grade (I or II vs. III)

We compared the prognosis according to the tumor grade stratified by 21-gene recurrence score

Sponsors & Collaborators

  • Gangnam Severance Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2025-12-31
Completion
2026-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07093775 on ClinicalTrials.gov